240.10

0.90% 2.14

After Hours: 240.50 0.40 +0.17%

Johnson Johnson (JNJ)

Overview News Price History Option Chain Financials Why JNJ Down? Discussions Forecast Stock Split Dividend History

Johnson Johnson stock is traded at $240.10, with a volume of 10.13M. It is up +0.90% in the last 24 hours and down -0.59% over the past month. Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.

Previous Close:

$237.96

Open:

$235.01

24h Volume:

10.13M

Relative Volume:

1.18

Market Cap:

$578.31B

Revenue:

$94.19B

Net Income/Loss:

$26.80B

P/E Ratio:

21.74

EPS:

11.0458

Net Cash Flow:

$19.70B

1W Performance:

+0.71%

1M Performance:

-0.59%

6M Performance:

+25.81%

1Y Performance:

+55.55%

1-Day Range:

$233.25

$242.19

1-Week Range:

$233.25

$244.20

52-Week Range:

$146.12

$251.71

Johnson Johnson Stock (JNJ) Company Profile

Name

Johnson Johnson

Sector

Healthcare (1110)

Industry

Drug Manufacturers - General (20)

Phone

732-524-2455

Address

ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK, NJ

Employee

140,800

Twitter

@jnjnews

Next Earnings Date

2026-04-14

Latest SEC Filings

JNJ's Discussions on Twitter

Compare JNJ vs LLY, ABBV, AZN, MRK

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
JNJ Johnson Johnson	240.10	574.36B	94.19B	26.80B	19.70B	11.05
LLY Lilly Eli Co	922.50	839.28B	65.18B	20.64B	5.96B	22.59
ABBV Abbvie Inc	210.26	367.80B	61.16B	4.19B	17.82B	2.3614
AZN Astrazeneca Plc	204.38	316.42B	58.80B	10.24B	8.98B	3.2788
MRK Merck Co Inc	119.96	299.89B	64.93B	18.26B	12.36B	7.2751

Johnson Johnson Stock (JNJ) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-08-26	Resumed	TD Cowen	Buy
Jan-28-26	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Nov-13-25	Initiated	Scotiabank	Sector Outperform
Oct-20-25	Upgrade	Daiwa Securities	Neutral → Outperform
Oct-03-25	Upgrade	Wells Fargo	Equal Weight → Overweight
Sep-23-25	Upgrade	Guggenheim	Neutral → Buy
Jul-23-25	Upgrade	Erste Group	Hold → Buy
May-13-25	Downgrade	Leerink Partners	Outperform → Market Perform
Dec-10-24	Resumed	BofA Securities	Neutral
Nov-15-24	Initiated	Wolfe Research	Outperform
Jul-23-24	Downgrade	Daiwa Securities	Outperform → Neutral
May-30-24	Resumed	Goldman	Neutral
Apr-18-24	Upgrade	HSBC Securities	Hold → Buy
Dec-13-23	Downgrade	Wells Fargo	Overweight → Equal Weight
Dec-01-23	Upgrade	UBS	Neutral → Buy
Oct-05-23	Initiated	RBC Capital Mkts	Outperform
Sep-06-23	Initiated	HSBC Securities	Hold
May-30-23	Resumed	Citigroup	Buy
Mar-29-23	Initiated	UBS	Neutral
Mar-01-23	Initiated	Guggenheim	Neutral
Nov-18-22	Initiated	Credit Suisse	Neutral
Oct-18-22	Initiated	Barclays	Equal Weight
Oct-14-22	Reiterated	BofA Securities	Neutral
Jun-22-22	Initiated	Daiwa Securities	Outperform
May-23-22	Resumed	SVB Leerink	Outperform
Apr-06-22	Resumed	Morgan Stanley	Equal-Weight
Mar-16-22	Downgrade	Bernstein	Outperform → Mkt Perform
Mar-02-22	Resumed	BofA Securities	Neutral
Dec-17-21	Initiated	Goldman	Neutral
Dec-15-21	Reiterated	Citigroup	Buy
Sep-07-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
May-28-21	Resumed	Morgan Stanley	Overweight
Apr-28-20	Downgrade	UBS	Buy → Neutral
Apr-22-20	Upgrade	BofA/Merrill	Neutral → Buy
Mar-05-20	Initiated	Citigroup	Buy
Dec-19-19	Upgrade	Barclays	Equal Weight → Overweight
Dec-17-19	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Nov-20-19	Initiated	Cantor Fitzgerald	Overweight
Oct-16-19	Upgrade	Atlantic Equities	Underweight → Neutral
Oct-11-19	Upgrade	Bernstein	Mkt Perform → Outperform
Jul-12-19	Resumed	Credit Suisse	Outperform
May-28-19	Initiated	Goldman	Buy
Jan-23-19	Reiterated	Barclays	Equal Weight
Jul-12-18	Upgrade	Goldman	Sell → Neutral
Jun-27-18	Initiated	Bernstein	Mkt Perform
Apr-23-18	Reiterated	Citigroup	Neutral
Apr-18-18	Reiterated	Stifel	Hold
Jan-24-18	Reiterated	Stifel	Hold
Jan-12-18	Reiterated	Wells Fargo	Outperform
Jan-02-18	Downgrade	JP Morgan	Overweight → Neutral
Oct-18-17	Reiterated	RBC Capital Mkts	Outperform
Oct-18-17	Reiterated	Stifel	Hold

View All

Johnson Johnson Stock (JNJ) Latest News

02:04 AM

Johnson Earns Bid to Portsmouth Invitational - Kansas State University Athletics

02:04 AM

12:55 PM

Johnson and Johnson Raises Dividend for 64th Consecutive Year - Yahoo Finance

12:55 PM

12:46 PM

Johnson & Johnson Q1 2026 Earnings Call Summary - Yahoo Finance

12:46 PM

12:33 PM

Carson Johnson Named to CSC Academic All-America Third Team - University of Denver Athletics

12:33 PM

11:44 AM

Jim Cramer on Johnson & Johnson: “If It Gets Blasted, Try to Get Some” - Yahoo Finance

11:44 AM

11:43 AM

J&J leans on Tremfya, cancer drugs to overcome Stelara losses - BioPharma Dive

11:43 AM

10:20 AM

Johnson & Johnson Announces 64th Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 3.1% - BioSpace

10:20 AM

10:13 AM

Johnson & Johnson Q1 Performance: Cancer Drug Revenue Grows, Free Cash Flow Falls, Hikes Dividend - Benzinga

10:13 AM

10:00 AM

Earvin ‘Magic’ Johnson brings 10,000-megawatt smile and inspiration to UIC Chair Chats - UIC today

10:00 AM

09:30 AM

Cramer's Mad Dash: Johnson & Johnson - CNBC

09:30 AM